<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26437449</article-id><article-id pub-id-type="pmc">4593549</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0139302</article-id><article-id pub-id-type="publisher-id">PONE-D-15-01817</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Effect of a Multi-Dimensional and Inter-Sectoral Intervention on the Adherence of Psychiatric Patients</article-title><alt-title alt-title-type="running-head">Intervention on Adherence in Psychiatry</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Pauly</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wolf</surname><given-names>Carolin</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Mayr</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="aff003">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lenz</surname><given-names>Bernd</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kornhuber</surname><given-names>Johannes</given-names></name><xref ref-type="aff" rid="aff002">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Friedland</surname><given-names>Kristina</given-names></name><xref ref-type="aff" rid="aff001">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001">
<label>1</label>
<addr-line>Molecular &#x00026; Clinical Pharmacy, Friedrich-Alexander University Erlangen-N&#x000fc;rnberg (FAU), Erlangen, Germany</addr-line>
</aff><aff id="aff002">
<label>2</label>
<addr-line>Department of Psychiatry and Psychotherapy, Friedrich-Alexander University Erlangen-N&#x000fc;rnberg (FAU), Erlangen, Germany</addr-line>
</aff><aff id="aff003">
<label>3</label>
<addr-line>Department of Medical Informatics, Biometry and Epidemiology, Friedrich-Alexander-University Erlangen-N&#x000fc;rnberg (FAU), Erlangen, Germany</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Davey</surname><given-names>Christopher G</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University of Melbourne, AUSTRALIA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: AP CW JK KF. Performed the experiments: AP CW. Analyzed the data: AP CW KF AM BL. Wrote the paper: AP CW AM BL JK KF.</p></fn><corresp id="cor001">* E-mail: <email>Kristina.Leuner@fau.de</email></corresp></author-notes><pub-date pub-type="epub"><day>5</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>10</volume><issue>10</issue><elocation-id>e0139302</elocation-id><history><date date-type="received"><day>17</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>8</day><month>9</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Pauly et al</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Pauly et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="pone.0139302.pdf"/><abstract><sec id="sec001"><title>Background</title><p>In psychiatry, hospital stays and transitions to the ambulatory sector are susceptible to major changes in drug therapy that lead to complex medication regimens and common non-adherence among psychiatric patients. A multi-dimensional and inter-sectoral intervention is hypothesized to improve the adherence of psychiatric patients to their pharmacotherapy.</p></sec><sec id="sec002"><title>Methods</title><p>269 patients from a German university hospital were included in a prospective, open, clinical trial with consecutive control and intervention groups. Control patients (09/2012-03/2013) received usual care, whereas intervention patients (05/2013-12/2013) underwent a program to enhance adherence during their stay and up to three months after discharge. The program consisted of therapy simplification and individualized patient education (multi-dimensional component) during the stay and at discharge, as well as subsequent phone calls after discharge (inter-sectoral component). Adherence was measured by the &#x0201c;Medication Adherence Report Scale&#x0201d; (MARS) and the &#x0201c;Drug Attitude Inventory&#x0201d; (DAI).</p></sec><sec id="sec003"><title>Results</title><p>The improvement in the MARS score between admission and three months after discharge was 1.33 points (95% CI: 0.73&#x02013;1.93) higher in the intervention group compared to controls. In addition, the DAI score improved 1.93 points (95% CI: 1.15&#x02013;2.72) more for intervention patients.</p></sec><sec id="sec004"><title>Conclusion</title><p>These two findings indicate significantly higher medication adherence following the investigated multi-dimensional and inter-sectoral program.</p></sec><sec id="sec005"><title>Trial Registration</title><p>German Clinical Trials Register <ext-link ext-link-type="uri" xlink:href="https://drks-neu.uniklinik-freiburg.de/DRKS00006358">DRKS00006358</ext-link>
</p></sec></abstract><funding-group><funding-statement>The study was funded by the &#x0201c;F&#x000f6;rderinitiative Pharmazeutische Betreuung e.V.&#x0201d; (<ext-link ext-link-type="uri" xlink:href="http://www.foerderinitiative.de">www.foerderinitiative.de</ext-link>). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="3"/><page-count count="17"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>Non-adherence to medication is one of the main causes for unsuccessful pharmacotherapy in psychiatry [<xref rid="pone.0139302.ref001" ref-type="bibr">1</xref>]. For example, the risk of hospitalization for non-adherent patients with schizophrenia is reported to be four times higher than for adherent patients [<xref rid="pone.0139302.ref002" ref-type="bibr">2</xref>]. It is assumed that increasing adherence might be the most efficacious way to further improve health care outcome [<xref rid="pone.0139302.ref003" ref-type="bibr">3</xref>].</p><p>Adherence is influenced by social and economic factors, the health care team/system, the characteristics of the disease, disease therapies and patient-related factors, as defined by the WHO [<xref rid="pone.0139302.ref003" ref-type="bibr">3</xref>]. Successful interventions should ideally target several of these dimensions because single-faceted interventions have frequently failed to show an impact [<xref rid="pone.0139302.ref004" ref-type="bibr">4</xref>]. Besides affecting practical barriers to adherence (e.g. dosing frequency), perceptual barriers, including the patient&#x02019;s individual risk-benefit-assessment, should also be addressed [<xref rid="pone.0139302.ref005" ref-type="bibr">5</xref>]. Thus far, this dimension has only been considered in a few studies [<xref rid="pone.0139302.ref005" ref-type="bibr">5</xref>].</p><p>Successful research aimed at improving adherence in psychiatric patients and at developing a program for daily clinical practice in the hospital is rare. Previous investigations mainly enhanced the patient&#x02019;s knowledge and insight [<xref rid="pone.0139302.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0139302.ref007" ref-type="bibr">7</xref>] and focused on outpatients [<xref rid="pone.0139302.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0139302.ref009" ref-type="bibr">9</xref>], but did not combine the beneficial therapy simplifications [<xref rid="pone.0139302.ref010" ref-type="bibr">10</xref>] with individualized patient education. The hospital stay and the time after discharge are periods that are susceptible to major changes in drug therapy that lead to patient uncertainty [<xref rid="pone.0139302.ref011" ref-type="bibr">11</xref>]. Hence, the transition between inpatient care and the ambulatory sector should be a point of focus by health care professionals.</p><p>Therefore, we investigated the effect of a multi-dimensional and inter-sectoral program on the patients&#x02019; adherence using a controlled study design in a psychiatric inpatient setting. The program started during the stay and ended three months after discharge. The additional program was administered only to patients in the intervention group. It included the provision of individualized verbal and written information regarding the patient&#x02019;s specific psychiatric medication and diseases with subsequent telephone calls after discharge that focused on the patients&#x02019; concerns about their pharmacotherapy as well as maintaining adherence. Additionally, a medication review targeting the simplification of the pharmacotherapeutic regimen was performed. Control patients received usual care that included the dispensing of medication by ward staff and group counseling about medication once during their stay. The patient&#x02019;s individual adherence was measured by the self-report questionnaires &#x0201c;Medication Adherence Report Scale&#x0201d; (MARS) [<xref rid="pone.0139302.ref012" ref-type="bibr">12</xref>] and &#x0201c;Drug Attitude Inventory&#x0201d; (DAI) [<xref rid="pone.0139302.ref013" ref-type="bibr">13</xref>] at admission, discharge and three months after discharge.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Materials and Methods</title><sec id="sec008"><title>Trial design</title><p>The study was designed as a non-randomized, prospective and open trial with a control and subsequent intervention group. The consecutive design was chosen to avoid a &#x0201c;carry-over effect&#x0201d; of methods from the intervention to the control group. Therefore, a parallel design with randomization was not possible.</p></sec><sec id="sec009"><title>Setting and participants</title><p>The study was conducted on two open wards with a total of 44 beds at the Department of Psychiatry and Psychotherapy of the maximum care University Hospital of Erlangen, Germany, which provides a total of 1300 beds. The Department of Psychiatry and Psychotherapy consists of two closed and two open wards as well as an ambulatory clinic and day clinic. An interdisciplinary team including psychiatrists, psychologists, nurses, occupational therapists, social workers and physiotherapists collaborate to help the patients during an acute disease crisis and with reintegration into society thereafter. All psychiatric diseases are treated with a particular focus on depression and anxiety disorders. The treatment comprises psychopharmacologic medication and non-drug interventions such as daily light, occupational and movement therapy as well as weekly psychological therapy.</p><p>Patients eligible for inclusion were &#x02265; 18 years who took at least one drug for a psychiatric condition, stayed a minimum of seven days on the ward and were able to communicate in German. Patients who met the inclusion criteria and gave written informed consent were assigned to the control or intervention group depending on the date of their admission. The control patients were included between September 2012 and March 2013 and the intervention patients between May and December 2013.</p></sec><sec id="sec010"><title>Ethics statement</title><p>The Ethics Committee of the Friedrich-Alexander University Erlangen-Nuremberg (FAU) approved the study protocol on 26.07.2012 (174_12 B). The trial was registered with the German Clinical Trials Register (<ext-link ext-link-type="uri" xlink:href="https://drks-neu.uniklinik-freiburg.de/DRKS00006358">DRKS00006358</ext-link>) and can be accessed via <ext-link ext-link-type="uri" xlink:href="https://drks-neu.uniklinik-freiburg.de">https://drks-neu.uniklinik-freiburg.de</ext-link>. The study was registered after enrolment of patients started because the responsible persons weren&#x02019;t aware of the need to register before. No significant changes were made to the study protocol after approval of the ethical committee. The authors confirm that all ongoing and related trials for this intervention are registered.</p></sec><sec id="sec011"><title>Usual care</title><p>Usual care concerning medication included daily dispensing of medication by nurses in tablet boxes with four sections for morning, noon, evening and night medication respectively. The patient information leaflet is provided upon request of the patient. Medication can be a subject in the weekly medical consultation, but is not standard. General, non-individualized information about psychiatric medication is provided in a group session once during the stay.</p></sec><sec id="sec012"><title>Intervention</title><p>A multi-dimensional intervention was chosen due to its reported superiority to single-dimensional interventions [<xref rid="pone.0139302.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0139302.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0139302.ref015" ref-type="bibr">15</xref>]. The intervention was designed to create a program that addressed more than one of the five aforementioned factors influencing adherence [<xref rid="pone.0139302.ref003" ref-type="bibr">3</xref>]. The resulting multi-dimensional program focused on patient- and medication-related factors. Since, according to the published literature, [<xref rid="pone.0139302.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0139302.ref018" ref-type="bibr">18</xref>] insight is one of the most important factors that improves adherence in mental health, the program was based on a psychoeducational intervention. However, because standardized psychoeducation alone is not always efficacious, the intervention was individualized and combined with a simplification of drug regimens [<xref rid="pone.0139302.ref019" ref-type="bibr">19</xref>]. Additionally, phone calls provided closure to the inter-sectoral gap.[<xref rid="pone.0139302.ref020" ref-type="bibr">20</xref>]</p><p>The multi-dimensional and inter-sectoral program included 1) medication management with a focus on a simplification of therapy regimen, 2) counseling of patients during the hospital stay with verbal and written information and a medication plan at discharge, 3) phone calls after discharge. As recommended in the literature [<xref rid="pone.0139302.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0139302.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0139302.ref022" ref-type="bibr">22</xref>], the intervention was personalized to meet the individual requirements of each patient. For example, the description of the side effects in the information leaflets was adjusted for every patient.</p><list list-type="order"><list-item><p>Weekly, two pharmacists on the ward conducted a chart review to assess reasonable simplifications of medication regimens. Simplifications included reducing dosing frequency when possible, discontinuing unnecessary drugs and adjusting the times that drugs were taken in order to achieve optimal efficacy, few side effects and a simple therapy regimen. The simplifications were adjusted to the individual needs of each patient. In the intervention phase, these recommendations were discussed with the attending ward physicians who, together with the patient, decided the final implementation of the changes. For example, a common simplification concerned the once-daily dosage of Venlafaxine as a retard preparation that had been frequently administered twice daily prior to the intervention period.</p><p>In addition, the two pharmacists conducted a medication management to detect and solve drug-related problems, including drug-drug interactions or inappropriate dosing. Further information is provided elsewhere (unpublished data Wolf et al, 2015).</p></list-item><list-item><p>All intervention group patients received an individual consultation about their respective psychiatric disease and drugs. The patients were counseled about indication, mechanism of action, doses, side effects, interactions and instructions for use by a pharmacist. Additionally, the patients were informed about the delayed onset of effect and, if applicable, about the necessity to take the drug in order to prevent a relapse after recovery. Every patient received individualized written material based on the current state of the literature [<xref rid="pone.0139302.ref023" ref-type="bibr">23</xref>]. The duration of the consultation was adjusted based on the patient&#x02019;s prior knowledge and desire to ask questions.</p><p>At discharge, the pharmacists provided intensive discharge counseling including a medication plan with information that included the trade name, active component, indication, required dosage and dosing schedule as well as administering information. The structure of the medication plan was based on the planned standardized medication plan for Germany [<xref rid="pone.0139302.ref024" ref-type="bibr">24</xref>].</p></list-item><list-item><p>During the follow up after discharge, the pharmacists telephoned the intervention group patients twice. The calls occurred 1.5 weeks and 6 weeks after discharge and were aimed at motivating the patient to maintain the pharmacotherapy, answering questions and being informed about possible changes made by the primary care provider. If necessary, for example, when a tendency toward suicidality was observed, a hospital psychiatrist was involved.</p></list-item></list></sec><sec id="sec013"><title>Outcome measures</title><p>The primary outcome was the change in adherence from baseline to follow-up three months after discharge as measured by the MARS [<xref rid="pone.0139302.ref012" ref-type="bibr">12</xref>]. The secondary outcome measure was the difference in attitude towards psychotropic drugs as determined by the DAI [<xref rid="pone.0139302.ref013" ref-type="bibr">13</xref>].</p><sec id="sec014"><title>MARS</title><p>The MARS (Medication Adherence Report Scale) is a 5-item self-report questionnaire that asks about adherence in a continuous and sympathetic way [<xref rid="pone.0139302.ref012" ref-type="bibr">12</xref>]. It was translated into German, validated and considered reliable [<xref rid="pone.0139302.ref013" ref-type="bibr">13</xref>]. The MARS has been used to assess non-adherence over a variety of medical conditions including psychiatric diseases [<xref rid="pone.0139302.ref025" ref-type="bibr">25</xref>].</p><p>The patients score their own medication taking behavior on a Likert-scale ranging from &#x02018;always&#x02019; (1 point), &#x02018;often&#x02019;, &#x02018;sometimes&#x02019;, &#x02018;rarely&#x02019; to &#x02018;never&#x02019; (5 points) in terms of the following parameters: forgetting medication, altering or omitting doses, taking less than instructed or discontinuing the medication. In the end, scores are summed up with a maximum of 25 and a minimum of 5. A higher score indicates more adherent behavior. To calculate a change score as a percentage, the maximal possible difference of 20 points is defined as 100%.</p><p>Item 1 of the MARS assesses unintentional non-adherence (forgetfulness), whereas items 2&#x02013;5 determine intentional non-adherence such as deliberate altering of the dose or suspending the medications.</p><p>A cut-off value is not defined by the original initiators of the MARS. However, cut-off values between 20 and 24 have been used previously [<xref rid="pone.0139302.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0139302.ref027" ref-type="bibr">27</xref>]. By applying a cut-off value to the MARS scores, the percentage of adherent patients can be determined. This can be advantageous when comparing adherence rates measured by different methods. Due to the skewed distribution and its utilization in previous studies [<xref rid="pone.0139302.ref028" ref-type="bibr">28</xref>], a cut-off value of 24 was defined.</p></sec><sec id="sec015"><title>DAI</title><p>The Drug Attitude Inventory (DAI) [<xref rid="pone.0139302.ref013" ref-type="bibr">13</xref>] is a widely used and well-established self-rating instrument that assesses a patient&#x02019;s attitude towards psychotropic drugs. The DAI score is associated with the degree of non-adherence [<xref rid="pone.0139302.ref029" ref-type="bibr">29</xref>]. Although the DAI was primarily designed for antipsychotic drugs, it is by now also used for a variety of psychiatric diseases such as depression [<xref rid="pone.0139302.ref030" ref-type="bibr">30</xref>], thereby justifying its use in this trial.</p><p>The DAI originally contained 30 items, but a shortened version with 10 items that are considered to be predictive for the entire set, was developed. Both versions show good test-retest reliability and discriminative validity as well as a high internal consistency [<xref rid="pone.0139302.ref031" ref-type="bibr">31</xref>,<xref rid="pone.0139302.ref032" ref-type="bibr">32</xref>]. The DAI-10 is more frequently used due to its simplicity and equal psychometric properties.</p><p>The DAI consists of 10 statements by patients with schizophrenia about their medications and includes subjective feelings as well as attitudes [<xref rid="pone.0139302.ref013" ref-type="bibr">13</xref>].</p><p>For every statement, the patients score whether it is true or false according to their own experiences with their drugs during the last four weeks. An answer indicating a positive attitude scores +1 point whereas an answer suggesting a negative attitude scores -1 point. A positive or negative sum score demonstrates a positive or negative attitude associated with (non-) adherence, respectively.</p></sec></sec><sec id="sec016"><title>Collection of baseline and outcome data</title><p>Baseline data was collected after written informed consent of the patient and enrollment in the study. The pharmacists conducted a patient interview to assess demographic details, the therapy regimen and baseline adherence values measured by the MARS and DAI.</p><p>At discharge and three months after discharge (follow-up), the current medication profile for each patient was recorded and assessed by a pharmacist. The MARS and DAI were completed by the patients again. The data collected three months after discharge was usually obtained by telephone unless the patient wanted to return to the hospital to talk in person.</p></sec><sec id="sec017"><title>Statistical analysis</title><p>The sample size estimation was based on a study conducted by Finley et al that reported a 15% difference of adherence in control and intervention groups [<xref rid="pone.0139302.ref033" ref-type="bibr">33</xref>]. A minimum sample size of 123 patients was computed to detect a difference that was statistically significant at the 5% level with a power of at least 80% [<xref rid="pone.0139302.ref034" ref-type="bibr">34</xref>]. The study of Finley et al was chosen because it involved a similar program consisting of medication management, patient education and telephone follow-up [<xref rid="pone.0139302.ref033" ref-type="bibr">33</xref>].</p><p>Descriptive statistics are presented as the mean with standard deviation or the median with interquartile ranges for continuous variables. Categorical variables were presented as numbers and percentages. To check for group differences due to the allocation by time of admission, Chi-Square-Test or Fisher&#x02019;s-Exact-Test were applied for categorical variables, while Student&#x02019;s-t-Test and Mann-Whitney-U-Test were used for continuous variables.</p><p>The analysis of the primary and secondary outcomes was conducted following the intention-to-treat principle. Missing outcome values were imputed with the last valid observation of the patient (e.g., the baseline value). A sensitivity analysis showed that this imputation approach was more conservative than a corresponding analysis of the complete sample that resulted in higher effect sizes (results not shown).</p><p>For both endpoints (MARS and DAI), statistical regression analysis was performed to estimate the effect of the intervention while adjusting for group differences at baseline. The change of the outcome variables between baseline and follow-up served as response variables, while the grouping variables, age, sex, comorbidities, number of medications at admission and the baseline score served as predictors. The estimated coefficient for the group variable therefore represents the adjusted effect of the intervention and was reported with a corresponding 95% CI. This procedure was repeated for both sum scores as well as for the single items.</p><p>Statistical analyses were performed using IBM SPSS Statistics for Windows Version 22.0 (SPSS Armonk, NY, USA: IBM Corp.) and the statistical programming environment R 3.0.2 (R Foundation for Statistical Computing, <ext-link ext-link-type="uri" xlink:href="http://www.R-project.org/">http://www.R-project.org/</ext-link>).</p></sec></sec><sec sec-type="results" id="sec018"><title>Results</title><sec id="sec019"><title>Baseline characteristics</title><p>A total of 269 patients were included. 136 patients admitted between September 2012 and March 2013 and who met the inclusion criteria were allocated to the control group. Three patients were discharged prior to the first pharmaceutical interview and consequently were not included in the analyses of baseline and outcome variables. Recruitment for the intervention group began in April 2013 and ended in December 2013. 133 patients were included in the intervention group. Again, two patients were discharged early and therefore excluded from the analysis. Mostly due to spontaneous discharge, the discharge assessment was not completed for 23 patients (15 control and 8 intervention). 109 control and 107 intervention group patients were followed for three months after discharge. One patient did not take any medications between discharge and follow-up. Consequently, the MARS and DAI score were not assessed resulting in a total of 263 patients for analysis of the MARS. Six patients did not take psychiatric drugs during the last four weeks before follow-up. The DAI was not assessed for them at follow-up resulting in 258 evaluable questionnaires. All analyses were carried out following the intention-to-treat principle with imputed values, if necessary, for 263 patients and 258 patients, respectively. (<xref rid="pone.0139302.g001" ref-type="fig">Fig 1</xref>)</p><fig id="pone.0139302.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0139302.g001</object-id><label>Fig 1</label><caption><title>Trial profile.</title><p>ITT, Intention To Treat. Flow chart of control and intervention patients from allocation to group to analysis of date.</p></caption><graphic xlink:href="pone.0139302.g001"/></fig><p>There were no significant differences between the two groups regarding demographic data such as marital and work status, nationality or living arrangements. Furthermore, the two groups did not differ significantly in terms of disease- and medication-related variables. The control group consisted of more patients with schizophrenia (F2, 9.8%) and fewer patients with anxiety disorders (F4, 15.0%) compared to the intervention group (6.9% and 19.8%, respectively). Additionally, intervention group patients stayed longer in hospital than control group patients. However, these differences were not statistically significant. Furthermore, patients in the intervention group were slightly older than the control patients. The intervention group consisted of a higher percentage of female patients and had more secondary diagnoses. These differences were considered in the statistical analysis. Mean MARS and DAI scores were similar in both groups at admission. (<xref rid="pone.0139302.t001" ref-type="table">Table 1</xref>)</p><table-wrap id="pone.0139302.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0139302.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of the study population.</title></caption><alternatives><graphic id="pone.0139302.t001g" xlink:href="pone.0139302.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Control (<italic>n</italic> = 133)</th><th align="center" rowspan="1" colspan="1">Intervention (<italic>n</italic> = 131)</th><th align="center" rowspan="1" colspan="1">
<italic>p</italic>-Value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Gender</bold> (<italic>n</italic> women (%))</td><td align="center" rowspan="1" colspan="1">43 (32.33%)</td><td align="center" rowspan="1" colspan="1">61 (46.56%)</td><td align="char" char="." rowspan="1" colspan="1">0.018<xref rid="t001fn002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Age</bold> (years (&#x000b1;SD))</td><td align="center" rowspan="1" colspan="1">45.44 (&#x000b1; 14.67)</td><td align="center" rowspan="1" colspan="1">49.10 (&#x000b1; 15.26)</td><td align="char" char="." rowspan="1" colspan="1">0.048<xref rid="t001fn003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Nationality</bold> (<italic>n</italic> (%))</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">German</td><td align="center" rowspan="1" colspan="1">120 (90.2%)</td><td align="center" rowspan="1" colspan="1">122 (93.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">other</td><td align="center" rowspan="1" colspan="1">13 (9.8%)</td><td align="center" rowspan="1" colspan="1">9 (6.9%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.393<xref rid="t001fn002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Living arrangements</bold> (<italic>n</italic> (%))</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">living with family</td><td align="center" rowspan="1" colspan="1">82 (61.7%)</td><td align="center" rowspan="1" colspan="1">89 (67.9%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">living alone</td><td align="center" rowspan="1" colspan="1">47 (35.3%)</td><td align="center" rowspan="1" colspan="1">39 (29.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">living in institution/sharing a flat</td><td align="center" rowspan="1" colspan="1">4 (3.0%)</td><td align="center" rowspan="1" colspan="1">3 (2.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.626<xref rid="t001fn005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Marital status</bold> (<italic>n</italic> (%))</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">married</td><td align="center" rowspan="1" colspan="1">67 (50.4%)</td><td align="center" rowspan="1" colspan="1">68 (51.9%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">single</td><td align="center" rowspan="1" colspan="1">44 (33.1%)</td><td align="center" rowspan="1" colspan="1">33 (25.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">divorced</td><td align="center" rowspan="1" colspan="1">17 (12.8%)</td><td align="center" rowspan="1" colspan="1">22 (16.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">widowed</td><td align="center" rowspan="1" colspan="1">5 (3.8%)</td><td align="center" rowspan="1" colspan="1">8 (6.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.405<xref rid="t001fn005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Work status</bold> (<italic>n</italic> (%))</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">employee</td><td align="center" rowspan="1" colspan="1">37 (27.8%)</td><td align="center" rowspan="1" colspan="1">49 (37.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">unemployed</td><td align="center" rowspan="1" colspan="1">25 (18.8%)</td><td align="center" rowspan="1" colspan="1">19 (14.5%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">pensioners</td><td align="center" rowspan="1" colspan="1">21 (15.8%)</td><td align="center" rowspan="1" colspan="1">23 (17.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">incapacitated</td><td align="center" rowspan="1" colspan="1">16 (12.0%)</td><td align="center" rowspan="1" colspan="1">14 (10.7%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">self-employed</td><td align="center" rowspan="1" colspan="1">7 (5.3%)</td><td align="center" rowspan="1" colspan="1">6 (4.6%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">official</td><td align="center" rowspan="1" colspan="1">7 (5.3%)</td><td align="center" rowspan="1" colspan="1">3 (2.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">other</td><td align="center" rowspan="1" colspan="1">20 (15.0%)</td><td align="center" rowspan="1" colspan="1">17 (13.0.0%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.604<xref rid="t001fn005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Education</bold> (<italic>n</italic> (%))</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">high-level</td><td align="center" rowspan="1" colspan="1">50 (37.6%)</td><td align="center" rowspan="1" colspan="1">44 (34.1%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">intermediate-level</td><td align="center" rowspan="1" colspan="1">72 (54.1%)</td><td align="center" rowspan="1" colspan="1">74 (57.4%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">low-level</td><td align="center" rowspan="1" colspan="1">7 (5.3%)</td><td align="center" rowspan="1" colspan="1">3 (2.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">other</td><td align="center" rowspan="1" colspan="1">4 (3.0%)</td><td align="center" rowspan="1" colspan="1">8 (6.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.376<xref rid="t001fn005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Prior psychiatric hospitalisations</bold> (<italic>n</italic> (%))</td><td colspan="2" align="center" rowspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">0&#x02013;1</td><td align="center" rowspan="1" colspan="1">73 (54.9%)</td><td align="center" rowspan="1" colspan="1">77 (58.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x02265; 2</td><td align="center" rowspan="1" colspan="1">60 (45.1%)</td><td align="center" rowspan="1" colspan="1">54 (41.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.523<xref rid="t001fn002" ref-type="table-fn">
<sup>a</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Number of drugs</bold> (Median (IQR))</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">at admission</td><td align="center" rowspan="1" colspan="1">4 (2&#x02013;6)</td><td align="center" rowspan="1" colspan="1">3 (2&#x02013;5)</td><td align="char" char="." rowspan="1" colspan="1">0.769<xref rid="t001fn004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">at discharge</td><td align="center" rowspan="1" colspan="1">4 (2&#x02013;6)</td><td align="center" rowspan="1" colspan="1">4 (2&#x02013;6)</td><td align="char" char="." rowspan="1" colspan="1">0.787<xref rid="t001fn004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">3 months after discharge</td><td align="center" rowspan="1" colspan="1">4 (2&#x02013;6)</td><td align="center" rowspan="1" colspan="1">3 (2&#x02013;6)</td><td align="char" char="." rowspan="1" colspan="1">0.577<xref rid="t001fn004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Psychiatric Diagnosis</bold> (<italic>n</italic> (%))</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mood (affective) disorder (F30-F39)</td><td align="center" rowspan="1" colspan="1">89 (66.9%)</td><td align="center" rowspan="1" colspan="1">88 (67.2%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Neurotic, stress-related and somatoform disorders (F40-F48)</td><td align="center" rowspan="1" colspan="1">20 (15.0%)</td><td align="center" rowspan="1" colspan="1">26 (19.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Schizophrenia, schizotypal and delusional disorders (F20-F29)</td><td align="center" rowspan="1" colspan="1">13 (9.8%)</td><td align="center" rowspan="1" colspan="1">9 (6.9%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Mental and behavioral disorders due to psychoactive substance use (F10-F19)</td><td align="center" rowspan="1" colspan="1">7 (5.3%)</td><td align="center" rowspan="1" colspan="1">5 (3.8%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="center" rowspan="1" colspan="1">4 (3.0%)</td><td align="center" rowspan="1" colspan="1">3 (2.3%)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1">0.747<xref rid="t001fn005" ref-type="table-fn">
<sup>d</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Length of stay in days</bold> (Median (IQR))</td><td align="center" rowspan="1" colspan="1">29.0 (20.0&#x02013;47.5)</td><td align="center" rowspan="1" colspan="1">35.0 (22.0&#x02013;49.0)</td><td align="char" char="." rowspan="1" colspan="1">0.160<xref rid="t001fn004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Number of comorbidities</bold> (Median (IQR))</td><td align="center" rowspan="1" colspan="1">2.00 (1&#x02013;4)</td><td align="left" rowspan="1" colspan="1">3.00 (2&#x02013;5)</td><td align="char" char="." rowspan="1" colspan="1">0.006<xref rid="t001fn004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Baseline MARS</bold> (Mean (SD))</td><td align="center" rowspan="1" colspan="1">22.23 (2.87)</td><td align="center" rowspan="1" colspan="1">22.02 (3.42)</td><td align="char" char="." rowspan="1" colspan="1">0.919<xref rid="t001fn004" ref-type="table-fn">
<sup>c</sup>
</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Baseline DAI</bold> (Mean (SD))</td><td align="center" rowspan="1" colspan="1">1.08 (3.45)</td><td align="center" rowspan="1" colspan="1">1.63 (3.75)</td><td align="char" char="." rowspan="1" colspan="1">0.215<xref rid="t001fn003" ref-type="table-fn">
<sup>b</sup>
</xref>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>IQR, Interquartile Range. DAI, Drug Attitude Inventory. MARS, Medication Adherence Report Scale. SD, Standard Deviation.</p></fn><fn id="t001fn002"><p>
<sup>a</sup>Chi-square-test,</p></fn><fn id="t001fn003"><p>
<sup>b</sup>Student&#x02019;s t-test,</p></fn><fn id="t001fn004"><p>
<sup>c</sup>Mann-Whitney-U-test,</p></fn><fn id="t001fn005"><p>
<sup>d</sup>Fisher&#x02019;s exact test.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec020"><title>Primary outcome measures</title><p>Self-reported adherence was measured by the MARS, which can range between 5 and 25 with a higher score indicating a more adherent behavior [<xref rid="pone.0139302.ref012" ref-type="bibr">12</xref>]. The mean (SD) MARS score of control patients increased during hospitalization from 22.23 (2.87) by 1.21 points (6.05%) to 23.44 (2.34). Three months after discharge, the MARS score decreased by 0.97 points (4.85%) near to its level at baseline, 22.47 (2.99). In the intervention group, the MARS score improved from 22.02 (3.42) at admission by 2.3 points (11.6%) to 24.34 (1.61) at discharge. This value declined by 0.59 points (2.95%) to 23.75 (2.08) at the follow-up. Considering the improvement of the MARS score from baseline to follow-up, the adjusted effect of the intervention was 1.33 points (95% CI 0.73&#x02013;1.93). (<xref rid="pone.0139302.g002" ref-type="fig">Fig 2</xref>) Importantly, 53.44% of the intervention group patients in comparison to 31.06% of patients in the control group achieved the possible maximum of 25 points in the MARS indicating a perfect adherent behavior. (<xref rid="pone.0139302.g003" ref-type="fig">Fig 3</xref>)</p><fig id="pone.0139302.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0139302.g002</object-id><label>Fig 2</label><caption><title>MARS scores.</title><p>Development of MARS Scores with median and interquartile ranges for control and intervention group from baseline to follow-up three months after discharge. MARS, Medication Adherence Report Scale.</p></caption><graphic xlink:href="pone.0139302.g002"/></fig><fig id="pone.0139302.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0139302.g003</object-id><label>Fig 3</label><caption><title>Distribution of MARS scores at follow-up.</title><p>Distribution of MARS scores in control and intervention group at follow-up three months after discharge. MARS, Medication Adherence Report Scale.</p></caption><graphic xlink:href="pone.0139302.g003"/></fig><p>Intentional and non-intentional non-adherence were increased similarly. The adjusted effect size for improvement in non-intentional non-adherence (item 1) was 0.27 points (95% CI 0.05&#x02013;0.49), for intentional non-adherence (items 2&#x02013;5) 0.96 points (95% CI 0.39&#x02013;1.51). (<xref rid="pone.0139302.t002" ref-type="table">Table 2</xref>)</p><table-wrap id="pone.0139302.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0139302.t002</object-id><label>Table 2</label><caption><title>Description of the individual items of the MARS.</title></caption><alternatives><graphic id="pone.0139302.t002g" xlink:href="pone.0139302.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Control mean (SD)</th><th colspan="2" align="center" rowspan="1">Intervention mean (SD)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">Follow-up</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">Follow-up</th><th align="center" rowspan="1" colspan="1">Adjusted effect<xref rid="t002fn002" ref-type="table-fn">*</xref>
</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr><tr><th align="left" rowspan="1" colspan="1">MARS item</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 133)</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 132)</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 131)</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 131)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">I forget to take them.</td><td align="center" rowspan="1" colspan="1">4.24 (0.87)</td><td align="center" rowspan="1" colspan="1">4.26 (0.88)</td><td align="center" rowspan="1" colspan="1">4.37 (0.80)</td><td align="center" rowspan="1" colspan="1">4.68 (0.57)</td><td align="char" char="." rowspan="1" colspan="1">0.27</td><td align="center" rowspan="1" colspan="1">0.05&#x02013;0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">I alter the dose.</td><td align="center" rowspan="1" colspan="1">4.36 (0.87)</td><td align="center" rowspan="1" colspan="1">4.45 (0.79)</td><td align="center" rowspan="1" colspan="1">4.31 (0.88)</td><td align="center" rowspan="1" colspan="1">4.74 (0.59)</td><td align="char" char="." rowspan="1" colspan="1">0.32</td><td align="center" rowspan="1" colspan="1">0.13&#x02013;0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">I stop taking them for a while.</td><td align="center" rowspan="1" colspan="1">4.65 (0.66)</td><td align="center" rowspan="1" colspan="1">4.67 (0.65)</td><td align="center" rowspan="1" colspan="1">4.52 (0.80)</td><td align="center" rowspan="1" colspan="1">4.84 (0.46)</td><td align="char" char="." rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">0.11&#x02013;0.42</td></tr><tr><td align="left" rowspan="1" colspan="1">I decide to miss out a dose.</td><td align="center" rowspan="1" colspan="1">4.52 (0.75)</td><td align="center" rowspan="1" colspan="1">4.58 (0.71)</td><td align="center" rowspan="1" colspan="1">4.47 (0.80)</td><td align="center" rowspan="1" colspan="1">4.78 (0.50)</td><td align="char" char="." rowspan="1" colspan="1">0.21</td><td align="center" rowspan="1" colspan="1">0.06&#x02013;0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">I take less than instructed.</td><td align="center" rowspan="1" colspan="1">4.45 (0.77)</td><td align="center" rowspan="1" colspan="1">4.52 (0.76)</td><td align="center" rowspan="1" colspan="1">4.35 (0.84)</td><td align="center" rowspan="1" colspan="1">4.71 (0.61)</td><td align="char" char="." rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">0.09&#x02013;0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Intentional Non-Adherence (Sum Score 2&#x02013;5)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>17.99 (2.72)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>18.21 (2.70)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>17.65 (3.12)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>19.07 (2.04)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>0.96</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.39&#x02013;1.51</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Sum Score MARS</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>22.23 (2.87)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>22.47 (2.99)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>22.02 (3.42)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>23.75 (2.08)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>1.33</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>0.73&#x02013;1.93</bold>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>CI, Confidence Interval. MARS, Medication Adherence Report Scale. SD, Standard Deviation.</p></fn><fn id="t002fn002"><p>*Estimated treatment effect from statistical regression model, adjusted for sex, age, comorbidities, number of medications at admission and the baseline MARS score.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec021"><title>Secondary outcome measures</title><p>Adherence in psychiatric patients is strongly affected by their attitude towards their medication [<xref rid="pone.0139302.ref013" ref-type="bibr">13</xref>]. Therefore, we used the DAI to investigate the self-reported attitude of our sample to further clarify the causes for non-adherence. The DAI ranges between -10 (negative attitude) and +10 (positive attitude) [<xref rid="pone.0139302.ref013" ref-type="bibr">13</xref>].</p><p>The mean (SD) DAI score increased in the control patients during their hospitalization from 1.08 (3.45) at baseline by 1.04 points (5.2%) to 2.12 (3.82) at discharge. After discharge, this value increased slightly until follow-up by 0.33 points (1.65%) to 2.45 (4.02). In the intervention patients, the DAI score improved from 1.63 (3.75) at baseline by 2.79 points (13.95%) to 4.42 (3.35) at discharge and by 0.37 points (1.85%) to 4.79 (3.39) at follow-up. Conclusively, the adjusted effect of the intervention on the improvement of the DAI score to follow-up was 1.93 points (95% CI 1.15&#x02013;2.72). At admission, 57.36% of the control group patients and 62.02% of the intervention group patients were classified as adherent (DAI &#x0003e; 0). In the control group, the percentage of patients regarded as adherent at discharge was 69.77% and three months after discharge, 72.09%. In contrast, the proportion of adherent patients in the intervention group increased to 87.60%, which was maintained until follow-up (= 87.60%). (<xref rid="pone.0139302.g004" ref-type="fig">Fig 4</xref>)</p><fig id="pone.0139302.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0139302.g004</object-id><label>Fig 4</label><caption><title>Fraction of adherent patients measured by the DAI.</title><p>Fraction of adherent patients in control group (open circle) and intervention group (filled circle) measured by the DAI. DAI, Drug Attitude Inventory.</p></caption><graphic xlink:href="pone.0139302.g004"/></fig><p>Regarding the individual items of the DAI, an (adjusted) effect can be observed for items 3 (&#x0201c;I take medications of my free choice.&#x0201d;), 6 (&#x0201c;I take medication only when I feel ill.&#x0201d;), 7 (&#x0201c;I feel more normal on medication.&#x0201d;) and 9 (&#x0201c;My thoughts are clearer on medication.&#x0201d;). (<xref rid="pone.0139302.t003" ref-type="table">Table 3</xref>)</p><table-wrap id="pone.0139302.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0139302.t003</object-id><label>Table 3</label><caption><title>Description of the individual items of the DAI.</title></caption><alternatives><graphic id="pone.0139302.t003g" xlink:href="pone.0139302.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Control mean (SD)</th><th colspan="2" align="center" rowspan="1">Intervention mean (SD)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">Follow-up</th><th align="center" rowspan="1" colspan="1">Baseline</th><th align="center" rowspan="1" colspan="1">Follow-up</th><th align="center" rowspan="1" colspan="1">Adjusted effect<xref rid="t003fn002" ref-type="table-fn">*</xref>
</th><th align="center" rowspan="1" colspan="1">95% CI</th></tr><tr><th align="left" rowspan="1" colspan="1">DAI item</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 133)</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 129)</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 131)</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 129)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">For me, the good things about medication outweigh the bad.</td><td align="center" rowspan="1" colspan="1">0.35 (0.52)</td><td align="center" rowspan="1" colspan="1">0.55 (0.56)</td><td align="center" rowspan="1" colspan="1">0.44 (0.56)</td><td align="center" rowspan="1" colspan="1">0.69 (0.44)</td><td align="char" char="." rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">-0.11&#x02013;0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">I feel strange, &#x0201e;doped up&#x0201c;, on medication.</td><td align="center" rowspan="1" colspan="1">0.36 (0.61)</td><td align="center" rowspan="1" colspan="1">0.59 (0.66)</td><td align="center" rowspan="1" colspan="1">0.54 (0.67)</td><td align="center" rowspan="1" colspan="1">0.76 (0.45)</td><td align="char" char="." rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">-0.04&#x02013;0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">I take medications of my free choice.</td><td align="center" rowspan="1" colspan="1">0.66 (0.60)</td><td align="center" rowspan="1" colspan="1">0.76 (0.50)</td><td align="center" rowspan="1" colspan="1">0.60 (0.70)</td><td align="center" rowspan="1" colspan="1">0.93 (0.28)</td><td align="char" char="." rowspan="1" colspan="1">0.24</td><td align="center" rowspan="1" colspan="1">0.06&#x02013;0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Medications make me feel more relaxed.</td><td align="center" rowspan="1" colspan="1">0.75 (0.69)</td><td align="center" rowspan="1" colspan="1">0.18 (0.76)</td><td align="center" rowspan="1" colspan="1">-0.03 (0.72)</td><td align="center" rowspan="1" colspan="1">0.22 (0.72)</td><td align="char" char="." rowspan="1" colspan="1">0.12</td><td align="center" rowspan="1" colspan="1">-0.08&#x02013;0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">Medications makes me feel tired and sluggish.</td><td align="center" rowspan="1" colspan="1">0.06 (0.66)</td><td align="center" rowspan="1" colspan="1">0.29 (0.69)</td><td align="center" rowspan="1" colspan="1">0.23 (0.68)</td><td align="center" rowspan="1" colspan="1">0.45 (0.64)</td><td align="char" char="." rowspan="1" colspan="1">0.06</td><td align="center" rowspan="1" colspan="1">-0.12&#x02013;0.24</td></tr><tr><td align="left" rowspan="1" colspan="1">I take medication only when I feel ill.</td><td align="center" rowspan="1" colspan="1">-0.16 (0.95)</td><td align="center" rowspan="1" colspan="1">0.03 (0.97)</td><td align="center" rowspan="1" colspan="1">-0.10 (0.96)</td><td align="center" rowspan="1" colspan="1">0.75 (0.64)</td><td align="char" char="." rowspan="1" colspan="1">0.69</td><td align="center" rowspan="1" colspan="1">0.43&#x02013;0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">I feel more normal on medication.</td><td align="center" rowspan="1" colspan="1">-0.11 (0.74)</td><td align="center" rowspan="1" colspan="1">-0.11 (0.82)</td><td align="center" rowspan="1" colspan="1">-0.14 (0.83)</td><td align="center" rowspan="1" colspan="1">0.12 (0.86)</td><td align="char" char="." rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">0.04&#x02013;0.49</td></tr><tr><td align="left" rowspan="1" colspan="1">It is unnatural for my mind and body to be controlled by medications.</td><td align="center" rowspan="1" colspan="1">0.11 (0.79)</td><td align="center" rowspan="1" colspan="1">0.25 (0.82)</td><td align="center" rowspan="1" colspan="1">0.19 (0.82)</td><td align="center" rowspan="1" colspan="1">0.48 (0.74)</td><td align="char" char="." rowspan="1" colspan="1">0.15</td><td align="center" rowspan="1" colspan="1">-0.06&#x02013;0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">My thoughts are clearer on medication.</td><td align="center" rowspan="1" colspan="1">-0.26 (0.71)</td><td align="center" rowspan="1" colspan="1">-0.28 (0.78)</td><td align="center" rowspan="1" colspan="1">-0.28 (0.78)</td><td align="center" rowspan="1" colspan="1">-0.05 (0.83)</td><td align="char" char="." rowspan="1" colspan="1">0.26</td><td align="center" rowspan="1" colspan="1">0.07&#x02013;0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">Taking medication will prevent me from having a breakdown.</td><td align="center" rowspan="1" colspan="1">-0.19 (0.76)</td><td align="center" rowspan="1" colspan="1">0.19 (0.81)</td><td align="center" rowspan="1" colspan="1">0.19 (0.84)</td><td align="center" rowspan="1" colspan="1">0.43 (0.74)</td><td align="char" char="." rowspan="1" colspan="1">0.08</td><td align="center" rowspan="1" colspan="1">-0.12&#x02013;0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Sum Score DAI</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.08 (3.45)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>2.45 (4.02)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.63 (3.75)</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>4.79 (3.39)</bold>
</td><td align="char" char="." rowspan="1" colspan="1">
<bold>1.93</bold>
</td><td align="center" rowspan="1" colspan="1">
<bold>1.15&#x02013;2.72</bold>
</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>CI, Confidence Interval. DAI, Drug Attitude Inventory. SD, Standard Deviation.</p></fn><fn id="t003fn002"><p>*Estimated treatment effect from statistical regression model, adjusted for sex, age, comorbidities, number of medications at admission and the baseline DAI score.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="conclusions" id="sec022"><title>Discussion</title><p>To our knowledge, this is the first controlled study that assessed the impact of a multi-dimensional and inter-sectoral program during hospitalization and after discharge on the adherence of psychiatric patients. We used the period of hospitalization for adherence enhancing interventions. In addition, the patients received telephone calls after discharge.</p><p>The complex intervention chosen for this study enhanced both non-intentional (item 1 of the MARS) and intentional non-adherence (item 2&#x02013;5 of the MARS). Although the difference between the control and intervention groups is highly significant at discharge and three months thereafter, it is striking that during hospitalization 26% of the intervention and 52% of the control patients were non-adherent. A study conducted with patients hospitalized in a department of internal medicine with an average length of stay of 9.3&#x000b1;6.8 days suggests that about 23% of patients are at least partly non-adherent during hospitalization [<xref rid="pone.0139302.ref035" ref-type="bibr">35</xref>]. As inpatient non-adherence is rarely investigated, possibly because it is perceived to be absent, we can only hypothesize that the higher percentage in our study could be explained by the longer duration of hospitalization of psychiatric patients e.g., 38.73 [29.25] days in our trial for the whole study population. It is conceivable that an extension or intensification of the interventions would achieve an even higher number of completely adherent patients.</p><p>Previous research exploring socio-demographic predictors of adherence has provided inconsistent results so far. It is rather evident that increasing age contributes to a more adherent behavior until a threshold of about 75 years when forgetfulness and frailty impede adherence [<xref rid="pone.0139302.ref005" ref-type="bibr">5</xref>]. The few studies investigating the impact of gender on adherence provide inconsistent results with a slight trend towards women being more adherent [<xref rid="pone.0139302.ref036" ref-type="bibr">36</xref>]. Additionally, the exact impact of the psychiatric diagnosis on adherence is still indistinct [<xref rid="pone.0139302.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0139302.ref038" ref-type="bibr">38</xref>], although the high rate of non-adherence in schizophrenia and its severe clinical impact have been well documented [<xref rid="pone.0139302.ref039" ref-type="bibr">39</xref>]. As generally chronic diseases have been associated with poorer adherence than acute diseases [<xref rid="pone.0139302.ref003" ref-type="bibr">3</xref>], the discrepancies in diagnoses between our control and intervention groups seem negligible. Although the statistical analysis has considered the statistically significant differences between the groups (age, gender and comorbidities), it cannot be excluded that the differences in terms of diagnosis or employment contribute to the better adherence in the intervention group.</p><p>It was interesting to observe that the adherence of control patients was increased during the hospitalization&#x02014;possibly by the usual interventions of the ward staff such as group sessions about medication&#x02014;but decreased after discharge to its original level. This implies that usual adherence supporting interventions are not completely sustainable. The valuable hospitalization time should be used to institute enduring interventions akin to the program described and assessed in this trial.</p><p>The difference between the groups in the DAI&#x02019;s item 3 (&#x0201c;I take medications of my free choice&#x0201d;) could suggest a higher sense of participation in the decision making process in the intervention patients, which has been reported to increase adherence [<xref rid="pone.0139302.ref040" ref-type="bibr">40</xref>]. The improvement in item 6 (&#x0201c;I take medication only when I feel ill&#x0201d;) seems to demonstrate a better knowledge about drug instructions in the intervention patients, possibly a result of the counseling provided by the pharmacists. The differences in items 7 and 9 could be attributed to a better response to pharmacotherapy, however a clinical outcome that would confirm this suggestion was not assessed.</p><p>Though the MARS [<xref rid="pone.0139302.ref012" ref-type="bibr">12</xref>] and DAI [<xref rid="pone.0139302.ref013" ref-type="bibr">13</xref>] are available as valid and reliable instruments, controlled studies in psychiatry that employ them are rare. De Las Cuevas et al used the DAI in a sample of depressed patients [<xref rid="pone.0139302.ref041" ref-type="bibr">41</xref>]. Firstly, they used the Morisky questionnaire to divide the study population into adherers and non-adherers. Then, they assessed a mean DAI score of 4.92 for adherent patients, which is comparable to the score measured in our study (4.79 at follow-up). An observational study by Medina et al reported a mean DAI score of 2.1 at discharge in patients with schizophrenia and bipolar patients [<xref rid="pone.0139302.ref042" ref-type="bibr">42</xref>], which corresponds to the DAI score of control patients (2.12) in our trial. Even though a high percentage achieved a DAI score &#x0003e; 0, the absolute scores of (non-) adherent patients remain rather low, between 2 and 5. This might indicate, in concordance with Brain et al, that the optimal DAI cut-off value to distinguish between adherers and non-adherers could be around 4 [<xref rid="pone.0139302.ref043" ref-type="bibr">43</xref>].</p><p>Canales et al conducted a controlled study with a similar interventional program in an American psychiatric inpatient setting, but did not follow patients after discharge [<xref rid="pone.0139302.ref044" ref-type="bibr">44</xref>]. They provided pharmacy services, including weekly medication reviews, pharmacotherapy recommendations and medication education. They did not assess adherence, but focused on several outcome parameters. Clinical response in the intervention patients was better, and there were less adverse effects. Even though the transferability of the results to the German health care setting and vice versa is not entirely possible, it can be assumed that the program's benefits would extend beyond adherence to include clinical outcomes.</p><p>There are several limitations concerning this study. First of all, the chosen method for measuring adherence was a self-report questionnaire. A patient&#x02019;s self-report is an indirect and subjective approach, and thus a less valid way of measuring adherence compared to direct methods [<xref rid="pone.0139302.ref010" ref-type="bibr">10</xref>]. Nonetheless, self-report is widely used due to its cost-effectiveness and practicality [<xref rid="pone.0139302.ref009" ref-type="bibr">9</xref>]. Velligan et al even asserted that data from subjective measurements were best correlated with the clinical state, thereby justifying the use of the MARS [<xref rid="pone.0139302.ref045" ref-type="bibr">45</xref>]. Jonsdottir et al demonstrated that the adherence measured by MARS correlated significantly to serum concentration of medication, but also ascertained a poor specificity [<xref rid="pone.0139302.ref046" ref-type="bibr">46</xref>]. The DAI is also reported to be a predictor of adherence measured objectively by MEMS [<xref rid="pone.0139302.ref043" ref-type="bibr">43</xref>].</p><p>Another principal limitation of the study is that it was designed as a non-randomized trial. Seasonal fluctuations and rotating physicians influence the patients&#x02019; behavior and lead to a possible over- as well as under-estimation of the intervention&#x02019;s effect size.</p><p>Another limitation concerns the choice of the interventional measures. Although psychoeducation on disease and drugs and simplification of drug regimens before discharge are no standard procedures in the study setting, many other hospitals have already included them in their routine. To enhance comparability and to avoid retesting of approved methods, it would have been favorable to shift the psychoeducation and simplification of drug regimens to usual care.</p><p>The study time was too short for measuring relapse and subsequent readmission to the hospital [<xref rid="pone.0139302.ref009" ref-type="bibr">9</xref>]. However, we hypothesize reduced relapse and readmission rates following the intervention because more adherent behavior has been shown to relate to improved clinical outcome [<xref rid="pone.0139302.ref047" ref-type="bibr">47</xref>], including reduced rates of relapses and re-hospitalizations [<xref rid="pone.0139302.ref048" ref-type="bibr">48</xref>,<xref rid="pone.0139302.ref049" ref-type="bibr">49</xref>]. It was beyond the scope of our trial to determine the impact of the intervention on these outcomes. Because numerous interventions fail to change the adherence due to narrow or non-individualized interventions [<xref rid="pone.0139302.ref004" ref-type="bibr">4</xref>], the results of this trial support a successful method that should be further investigated with respect to clinical and economic outcomes.</p><p>It would have been favorable to divide the study population into subgroups to determine the impact of the single interventions in comparison to the whole program. Since this was not carried out, the identification of the most efficacious component of the program is not possible. However, it has already been established that standardized psychoeducation alone is not effective for promoting adherence [<xref rid="pone.0139302.ref014" ref-type="bibr">14</xref>]. We speculate that the promising element of individualization in our psychoeducational program is a main factor underlying the observed effect.</p><p>In conclusion, it can be determined that the implementation of a multi-dimensional and inter-sectoral program enhances the patients&#x02019; adherence significantly up to three months after discharge. Considering the strong need for successful interventions to improve adherence among psychiatric patients, further studies are needed to explore the impact on clinical and economic outcomes.</p></sec><sec sec-type="supplementary-material" id="sec023"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0139302.s001"><label>S1 File</label><caption><title>Trial protocol as accepted by ethics committee_German.</title><p>(PDF)</p></caption><media xlink:href="pone.0139302.s001.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0139302.s002"><label>S2 File</label><caption><title>Trial protocol as accepted by ethics committee_English.</title><p>(PDF)</p></caption><media xlink:href="pone.0139302.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0139302.s003"><label>S3 File</label><caption><title>CONSORT Statement.</title><p>(PDF)</p></caption><media xlink:href="pone.0139302.s003.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors thank the &#x0201c;Department of General Practice and Health Services Research and Department of Internal Medicine VI, Clinical Pharmacology and Pharmacoepidemiology, University Hospital Heidelberg, Heidelberg, Germany&#x0201d; for the provision of the German version of the MARS.</p></ack><ref-list><title>References</title><ref id="pone.0139302.ref001"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Chapman</surname><given-names>SCE</given-names></name>, <name><surname>Horne</surname><given-names>R</given-names></name> (<year>2013</year>) <article-title>Medication nonadherence and psychiatry</article-title>. <source>Curr Opin Psychiatry</source>
<volume>26</volume>: <fpage>446</fpage>&#x02013;<lpage>452</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84881377249&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84881377249&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 1 April 2014.
<pub-id pub-id-type="pmid">23880592</pub-id></mixed-citation></ref><ref id="pone.0139302.ref002"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Morken</surname><given-names>G</given-names></name>, <name><surname>Widen</surname><given-names>JH</given-names></name>, <name><surname>Grawe</surname><given-names>RW</given-names></name> (<year>2008</year>) <article-title>Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia</article-title>. <source>BMC Psychiatry</source>
<volume>8</volume>: <fpage>32</fpage> Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-44249114045&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-44249114045&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 26 November 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1471-244X-8-32">10.1186/1471-244X-8-32</ext-link></comment>
<pub-id pub-id-type="pmid">18447935</pub-id></mixed-citation></ref><ref id="pone.0139302.ref003"><label>3</label><mixed-citation publication-type="book">
<name><surname>Sabate</surname><given-names>E</given-names></name> (<year>2003</year>) <source>Adherence to long-term therapies: evidence for action</source>. <publisher-name>World Heal Organ</publisher-name> Available: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1">http://www.who.int/chp/knowledge/publications/adherence_full_report.pdf?ua=1</ext-link>.</mixed-citation></ref><ref id="pone.0139302.ref004"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Haynes</surname><given-names>RB</given-names></name>, <name><surname>Ackloo</surname><given-names>E</given-names></name>, <name><surname>Sahota</surname><given-names>N</given-names></name>, <name><surname>McDonald</surname><given-names>HP</given-names></name>, <name><surname>Yao</surname><given-names>X</given-names></name> (<year>2008</year>) <article-title>Interventions for enhancing medication adherence</article-title>. <source>Cochrane database Syst Rev</source>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-44949190590&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-44949190590&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 13 July 2014. </mixed-citation></ref><ref id="pone.0139302.ref005"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Horne</surname><given-names>R</given-names></name>, <name><surname>Weinman</surname><given-names>J</given-names></name>, <name><surname>Barber</surname><given-names>N</given-names></name>, <name><surname>Elliott</surname><given-names>R</given-names></name> (<year>2005</year>) <article-title>Concordance, adherence and compliance in medicine taking</article-title>. <source>Rep Natl Co-ord Cent NHS Serv Deliv Organ R D</source>: <fpage>1</fpage>&#x02013;<lpage>331</lpage>.</mixed-citation></ref><ref id="pone.0139302.ref006"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Al-Saffar</surname><given-names>N</given-names></name>, <name><surname>Deshmukh</surname><given-names>AA</given-names></name>, <name><surname>Carter</surname><given-names>P</given-names></name>, <name><surname>Adib</surname><given-names>SM</given-names></name> (<year>2005</year>) <article-title>Effect of information leaflets and counselling on antidepressant adherence: open randomised controlled trial in a psychiatric hospital in Kuwait</article-title>. <source>Int J Pharm Pract</source>
<volume>13</volume>: <fpage>123</fpage>&#x02013;<lpage>132</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-20444415664&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-20444415664&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 18 July 2014.</mixed-citation></ref><ref id="pone.0139302.ref007"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Finley</surname><given-names>PR</given-names></name>, <name><surname>Rens</surname><given-names>HR</given-names></name>, <name><surname>Pont</surname><given-names>JT</given-names></name>, <name><surname>Gess</surname><given-names>SL</given-names></name>, <name><surname>Louie</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Impact of a collaborative care model on depression in a primary care setting: A randomized controlled trial</article-title>. <source>Pharmacotherapy</source>
<volume>23</volume>: <fpage>1175</fpage>&#x02013;<lpage>1185</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0141456709&#x00026;partnerID=40&#x00026;md5=bcf231ac26d91d3b93b53d1fa1185de7">http://www.scopus.com/inward/record.url?eid=2-s2.0-0141456709&#x00026;partnerID=40&#x00026;md5=bcf231ac26d91d3b93b53d1fa1185de7</ext-link>.
<pub-id pub-id-type="pmid">14524649</pub-id></mixed-citation></ref><ref id="pone.0139302.ref008"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Rubio-Valera</surname><given-names>M</given-names></name>, <name><surname>Serrano-Blanco</surname><given-names>A</given-names></name>, <name><surname>Magdalena-Bel&#x000ed;o</surname><given-names>J</given-names></name>, <name><surname>Fern&#x000e1;ndez</surname><given-names>A</given-names></name>, <name><surname>Garc&#x000ed;a-Campayo</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Effectiveness of pharmacist care in the improvement of adherence to antidepressants: a systematic review and meta-analysis</article-title>. <source>Ann Pharmacother</source>
<volume>45</volume>: <fpage>39</fpage>&#x02013;<lpage>48</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-78751548096&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-78751548096&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 17 July 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1345/aph.1P429">10.1345/aph.1P429</ext-link></comment>
<pub-id pub-id-type="pmid">21205952</pub-id></mixed-citation></ref><ref id="pone.0139302.ref009"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Al-Jumah</surname><given-names>KA</given-names></name>, <name><surname>Qureshi</surname><given-names>NA</given-names></name> (<year>2012</year>) <article-title>Impact of pharmacist interventions on patients&#x02019; adherence to antidepressants and patient-reported outcomes: A systematic review</article-title>. <source>Patient Prefer Adherence</source>
<volume>6</volume>: <fpage>87</fpage>&#x02013;<lpage>100</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84857088941&#x00026;partnerID=40&#x00026;md5=5a25bc5889e0584e4c794d7ad1c4b03d">http://www.scopus.com/inward/record.url?eid=2-s2.0-84857088941&#x00026;partnerID=40&#x00026;md5=5a25bc5889e0584e4c794d7ad1c4b03d</ext-link>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/PPA.S27436">10.2147/PPA.S27436</ext-link></comment>
<pub-id pub-id-type="pmid">22346345</pub-id></mixed-citation></ref><ref id="pone.0139302.ref010"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Osterberg</surname><given-names>L</given-names></name>, <name><surname>Blaschke</surname><given-names>T</given-names></name> (<year>2005</year>) <article-title>Adherence to medication</article-title>. <source>N Engl J Med</source>
<volume>353</volume>: <fpage>487</fpage>&#x02013;<lpage>497</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-23044442340&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-23044442340&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 11 July 2014.
<pub-id pub-id-type="pmid">16079372</pub-id></mixed-citation></ref><ref id="pone.0139302.ref011"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Viktil</surname><given-names>KK</given-names></name>, <name><surname>Blix</surname><given-names>HS</given-names></name>, <name><surname>Eek</surname><given-names>AK</given-names></name>, <name><surname>Davies</surname><given-names>MN</given-names></name>, <name><surname>Moger</surname><given-names>TA</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>How are drug regimen changes during hospitalisation handled after discharge: a cohort study</article-title>. <source>BMJ Open</source>
<volume>2</volume> Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84873165480&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84873165480&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 24 October 2014.</mixed-citation></ref><ref id="pone.0139302.ref012"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Horne</surname><given-names>R</given-names></name>, <name><surname>Weinman</surname><given-names>J</given-names></name> (<year>1999</year>) <article-title>Patients&#x02019; beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness</article-title>. <source>J Psychosom Res</source>
<volume>47</volume>: <fpage>555</fpage>&#x02013;<lpage>567</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0033398683&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-0033398683&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 20 July 2014.
<pub-id pub-id-type="pmid">10661603</pub-id></mixed-citation></ref><ref id="pone.0139302.ref013"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Hogan</surname><given-names>TP</given-names></name>, <name><surname>Awad</surname><given-names>AG</given-names></name>, <name><surname>Eastwood</surname><given-names>R</given-names></name> (<year>1983</year>) <article-title>A self-report scale predictive of drug compliance in schizophrenics: Reliability and discriminative validity</article-title>. <source>Psychol Med</source>
<volume>13</volume>: <fpage>177</fpage>&#x02013;<lpage>183</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0020535524&#x00026;partnerID=40&#x00026;md5=40e0532c73331d98bb1eeebcb909452c">http://www.scopus.com/inward/record.url?eid=2-s2.0-0020535524&#x00026;partnerID=40&#x00026;md5=40e0532c73331d98bb1eeebcb909452c</ext-link>.
<pub-id pub-id-type="pmid">6133297</pub-id></mixed-citation></ref><ref id="pone.0139302.ref014"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Chong</surname><given-names>WW</given-names></name>, <name><surname>Aslani</surname><given-names>P</given-names></name>, <name><surname>Chen</surname><given-names>TF</given-names></name> (<year>2011</year>) <article-title>Effectiveness of interventions to improve antidepressant medication adherence: a systematic review</article-title>. <source>Int J Clin Pract</source>
<volume>65</volume>: <fpage>954</fpage>&#x02013;<lpage>975</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-80051887513&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-80051887513&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 18 July 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1742-1241.2011.02746.x">10.1111/j.1742-1241.2011.02746.x</ext-link></comment>
<pub-id pub-id-type="pmid">21849010</pub-id></mixed-citation></ref><ref id="pone.0139302.ref015"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Roter</surname><given-names>DL</given-names></name>, <name><surname>Hall</surname><given-names>JA</given-names></name>, <name><surname>Merisca</surname><given-names>R</given-names></name>, <name><surname>Nordstrom</surname><given-names>B</given-names></name>, <name><surname>Cretin</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>1998</year>) <article-title>Effectiveness of Interventions to Improve Patient Compliance a Meta-Analysis</article-title>. <source>Med Care</source>
<volume>36</volume>: <fpage>1138</fpage>&#x02013;<lpage>1161</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0032135104&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-0032135104&#x00026;partnerID=tZOtx3y1</ext-link>.
<pub-id pub-id-type="pmid">9708588</pub-id></mixed-citation></ref><ref id="pone.0139302.ref016"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Julius</surname><given-names>RJ</given-names></name>, <name><surname>Novitsky</surname><given-names>MA</given-names></name>, <name><surname>Dubin</surname><given-names>WR</given-names></name> (<year>2009</year>) <article-title>Medication adherence: a review of the literature and implications for clinical practice</article-title>. <source>J Psychiatr Pract</source>
<volume>15</volume>: <fpage>34</fpage>&#x02013;<lpage>44</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-67650105447&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-67650105447&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 25 July 2014.
<pub-id pub-id-type="pmid">19182563</pub-id></mixed-citation></ref><ref id="pone.0139302.ref017"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Kasper</surname><given-names>S</given-names></name>, <name><surname>Saya</surname><given-names>L</given-names></name>, <name><surname>Tekin</surname><given-names>B</given-names></name>, <name><surname>Loze</surname><given-names>JY</given-names></name> (<year>2009</year>) <article-title>How to improve adherence to antipsychotic treatment: Outcomes of the IMproving PAtient outComes in psychiaTry (IMPACT) Berlin 2009 meeting workshop</article-title>. <source>Int J Psychiatry Clin Pract</source>
<volume>13</volume>: <fpage>245</fpage>&#x02013;<lpage>252</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-70350746378&#x00026;partnerID=40&#x00026;md5=a871232f16dc2758360d105b20dfa393">http://www.scopus.com/inward/record.url?eid=2-s2.0-70350746378&#x00026;partnerID=40&#x00026;md5=a871232f16dc2758360d105b20dfa393</ext-link>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3109/13651500903359861">10.3109/13651500903359861</ext-link></comment>
<pub-id pub-id-type="pmid">24916932</pub-id></mixed-citation></ref><ref id="pone.0139302.ref018"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Mohamed</surname><given-names>S</given-names></name>, <name><surname>Rosenheck</surname><given-names>R</given-names></name>, <name><surname>He</surname><given-names>H</given-names></name>, <name><surname>Yuping</surname><given-names>N</given-names></name> (<year>2014</year>) <article-title>Insight and attitudes towards medication among inpatients with chronic schizophrenia in the US and China</article-title>. <source>Soc Psychiatry Psychiatr Epidemiol</source>
<volume>49</volume>: <fpage>1063</fpage>&#x02013;<lpage>1070</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84903765807&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84903765807&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 18 July 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00127-014-0824-1">10.1007/s00127-014-0824-1</ext-link></comment>
<pub-id pub-id-type="pmid">24549835</pub-id></mixed-citation></ref><ref id="pone.0139302.ref019"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Farooq</surname><given-names>S</given-names></name>, <name><surname>Naeem</surname><given-names>F</given-names></name> (<year>2014</year>) <article-title>Tackling nonadherence in psychiatric disorders: current opinion</article-title>. <source>Neuropsychiatr Dis Treat</source>
<volume>10</volume>: <fpage>1069</fpage>&#x02013;<lpage>1077</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84902304759&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84902304759&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 21 July 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/NDT.S40777">10.2147/NDT.S40777</ext-link></comment>
<pub-id pub-id-type="pmid">24966677</pub-id></mixed-citation></ref><ref id="pone.0139302.ref020"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Mistiaen</surname><given-names>P</given-names></name>, <name><surname>Poot</surname><given-names>E</given-names></name> (<year>2006</year>) <article-title>Telephone follow-up, initiated by a hospital-based health professional, for postdischarge problems in patients discharged from hospital to home</article-title>. <source>Cochrane database Syst Rev</source>: <fpage>CD004510</fpage> Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-42749105095&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-42749105095&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 11 December 2014.
<pub-id pub-id-type="pmid">17054207</pub-id></mixed-citation></ref><ref id="pone.0139302.ref021"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Zullig</surname><given-names>LL</given-names></name>, <name><surname>Peterson</surname><given-names>ED</given-names></name>, <name><surname>Bosworth</surname><given-names>HB</given-names></name> (<year>2013</year>) <article-title>Ingredients of successful interventions to improve medication adherence</article-title>. <source>JAMA</source>
<volume>310</volume>: <fpage>2611</fpage>&#x02013;<lpage>2612</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84890905739&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84890905739&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 11 April 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.2013.282818">10.1001/jama.2013.282818</ext-link></comment>
<pub-id pub-id-type="pmid">24264605</pub-id></mixed-citation></ref><ref id="pone.0139302.ref022"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Cutrona</surname><given-names>SL</given-names></name>, <name><surname>Choudhry</surname><given-names>NK</given-names></name>, <name><surname>Fischer</surname><given-names>MA</given-names></name>, <name><surname>Servi</surname><given-names>A</given-names></name>, <name><surname>Liberman</surname><given-names>JN</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Modes of delivery for interventions to improve cardiovascular medication adherence</article-title>. <source>Am J Manag Care</source>
<volume>16</volume>: <fpage>929</fpage>&#x02013;<lpage>942</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-78650957841&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-78650957841&#x00026;partnerID=tZOtx3y1</ext-link>.
<pub-id pub-id-type="pmid">21348564</pub-id></mixed-citation></ref><ref id="pone.0139302.ref023"><label>23</label><mixed-citation publication-type="book">
<name><surname>Benkert</surname><given-names>O</given-names></name>, <name><surname>Hippius</surname><given-names>H</given-names></name> (<year>2013</year>) <source>Compendium of psychiatric pharmacotherapy</source>. <publisher-name>Springer-Verlag London Ltd</publisher-name>.</mixed-citation></ref><ref id="pone.0139302.ref024"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Aly</surname><given-names>AF</given-names></name> (<year>2013</year>) <article-title>Der einheitliche Medikationsplan: Standardisierte Informationsquelle f&#x000fc;r die Arzneimitteltherapie</article-title>. <source>Krankenhauspharmazie</source>
<volume>34</volume>: <fpage>240</fpage>&#x02013;<lpage>241</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84878249698&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84878249698&#x00026;partnerID=tZOtx3y1</ext-link>.</mixed-citation></ref><ref id="pone.0139302.ref025"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Bowskill</surname><given-names>R</given-names></name>, <name><surname>Clatworthy</surname><given-names>J</given-names></name>, <name><surname>Parham</surname><given-names>R</given-names></name>, <name><surname>Rank</surname><given-names>T</given-names></name>, <name><surname>Horne</surname><given-names>R</given-names></name> (<year>2007</year>) <article-title>Patients&#x02019; perceptions of information received about medication prescribed for bipolar disorder: implications for informed choice</article-title>. <source>J Affect Disord</source>
<volume>100</volume>: <fpage>253</fpage>&#x02013;<lpage>257</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-34249281242&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-34249281242&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 26 March 2014.
<pub-id pub-id-type="pmid">17174406</pub-id></mixed-citation></ref><ref id="pone.0139302.ref026"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Butler</surname><given-names>JA</given-names></name>, <name><surname>Peveler</surname><given-names>RC</given-names></name>, <name><surname>Roderick</surname><given-names>P</given-names></name>, <name><surname>Horne</surname><given-names>R</given-names></name>, <name><surname>Mason</surname><given-names>JC</given-names></name> (<year>2004</year>) <article-title>Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring</article-title>. <source>Transplantation</source>
<volume>77</volume>: <fpage>786</fpage>&#x02013;<lpage>789</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-1642364925&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-1642364925&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 25 March 2014.
<pub-id pub-id-type="pmid">15021850</pub-id></mixed-citation></ref><ref id="pone.0139302.ref027"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Clatworthy</surname><given-names>J</given-names></name>, <name><surname>Price</surname><given-names>D</given-names></name>, <name><surname>Ryan</surname><given-names>D</given-names></name>, <name><surname>Haughney</surname><given-names>J</given-names></name>, <name><surname>Horne</surname><given-names>R</given-names></name> (<year>2009</year>) <article-title>The value of self-report assessment of adherence, rhinitis and smoking in relation to asthma control</article-title>. <source>Prim Care Respir J</source>
<volume>18</volume>: <fpage>300</fpage>&#x02013;<lpage>305</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-70849100662&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-70849100662&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 21 July 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.4104/pcrj.2009.00037">10.4104/pcrj.2009.00037</ext-link></comment>
<pub-id pub-id-type="pmid">19562233</pub-id></mixed-citation></ref><ref id="pone.0139302.ref028"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Stange</surname><given-names>D</given-names></name>, <name><surname>Kriston</surname><given-names>L</given-names></name>, <name><surname>von-Wolff</surname><given-names>A</given-names></name>, <name><surname>Baehr</surname><given-names>M</given-names></name>, <name><surname>Dartsch</surname><given-names>DC</given-names></name> (<year>2013</year>) <article-title>Reducing cardiovascular medication complexity in a german university hospital: Effects of a structured pharmaceutical management intervention on adherence</article-title>. <source>J Manag Care Pharm</source>
<volume>19</volume>: <fpage>396</fpage>&#x02013;<lpage>407</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84878983373&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84878983373&#x00026;partnerID=tZOtx3y1</ext-link>.
<pub-id pub-id-type="pmid">23697477</pub-id></mixed-citation></ref><ref id="pone.0139302.ref029"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Awad</surname><given-names>AG</given-names></name> (<year>1993</year>) <article-title>Subjective response to neuroleptics in schizophrenia</article-title>. <source>Schizophr Bull</source>
<volume>19</volume>: <fpage>609</fpage>&#x02013;<lpage>618</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0027185944&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-0027185944&#x00026;partnerID=tZOtx3y1</ext-link>.
<pub-id pub-id-type="pmid">7901897</pub-id></mixed-citation></ref><ref id="pone.0139302.ref030"><label>30</label><mixed-citation publication-type="journal">
<name><surname>De Las Cuevas</surname><given-names>C</given-names></name>, <name><surname>Sanz</surname><given-names>EJ</given-names></name> (<year>2007</year>) <article-title>Attitudes toward psychiatric drug treatment: the experience of being treated</article-title>. <source>Eur J Clin Pharmacol</source>
<volume>63</volume>: <fpage>1063</fpage>&#x02013;<lpage>1067</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-35248844992&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-35248844992&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 18 July 2014.
<pub-id pub-id-type="pmid">17701404</pub-id></mixed-citation></ref><ref id="pone.0139302.ref031"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Hogan</surname><given-names>TP</given-names></name>, <name><surname>Awad</surname><given-names>AG</given-names></name> (<year>1992</year>) <article-title>Subjective response to neuroleptics and outcome in schizophrenia: A re-examination comparing two measures</article-title>. <source>Psychol Med</source>
<volume>22</volume>: <fpage>347</fpage>&#x02013;<lpage>352</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0026721876&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-0026721876&#x00026;partnerID=tZOtx3y1</ext-link>.
<pub-id pub-id-type="pmid">1615101</pub-id></mixed-citation></ref><ref id="pone.0139302.ref032"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Nielsen</surname><given-names>RE</given-names></name>, <name><surname>Lindstr&#x000f6;m</surname><given-names>E</given-names></name>, <name><surname>Nielsen</surname><given-names>J</given-names></name>, <name><surname>Levander</surname><given-names>S</given-names></name> (<year>2012</year>) <article-title>DAI-10 is as good as DAI-30 in schizophrenia</article-title>. <source>Eur Neuropsychopharmacol</source>
<volume>22</volume>: <fpage>747</fpage>&#x02013;<lpage>750</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84865565648&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84865565648&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 7 April 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.euroneuro.2012.02.008">10.1016/j.euroneuro.2012.02.008</ext-link></comment>
<pub-id pub-id-type="pmid">22440974</pub-id></mixed-citation></ref><ref id="pone.0139302.ref033"><label>33</label><mixed-citation publication-type="journal">
<name><surname>Finley</surname><given-names>PR</given-names></name>, <name><surname>Rens</surname><given-names>HR</given-names></name>, <name><surname>Pont</surname><given-names>JT</given-names></name>, <name><surname>Gess</surname><given-names>SL</given-names></name>, <name><surname>Louie</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>Impact of a collaborative pharmacy practice model on the treatment of depression in primary care</article-title>. <source>Am J Heal Pharm</source>
<volume>59</volume>: <fpage>1518</fpage>&#x02013;<lpage>1526</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0037101866&#x00026;partnerID=40&#x00026;md5=7ac9f53e720ea122931fb6be00891080">http://www.scopus.com/inward/record.url?eid=2-s2.0-0037101866&#x00026;partnerID=40&#x00026;md5=7ac9f53e720ea122931fb6be00891080</ext-link>.</mixed-citation></ref><ref id="pone.0139302.ref034"><label>34</label><mixed-citation publication-type="journal">
<name><surname>Kranke</surname><given-names>P</given-names></name>, <name><surname>Schuster</surname><given-names>F</given-names></name>, <name><surname>Muellenbach</surname><given-names>R</given-names></name>, <name><surname>Kranke</surname><given-names>EM</given-names></name>, <name><surname>Roewer</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Grundlagen und Prinzipien klinischer Studien: Wie viele Patienten sollen (m&#x000fc;ssen) untersucht werden? Fallzahlsch&#x000e4;tzung in klinischen Studien</article-title>. <source>Kardiotechnik</source>
<volume>17</volume>: <fpage>114</fpage>&#x02013;<lpage>117</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-57649136654&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-57649136654&#x00026;partnerID=tZOtx3y1</ext-link>.</mixed-citation></ref><ref id="pone.0139302.ref035"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Carow</surname><given-names>F</given-names></name>, <name><surname>Rieger</surname><given-names>K</given-names></name>, <name><surname>Walter-Sack</surname><given-names>I</given-names></name>, <name><surname>Meyer</surname><given-names>M</given-names></name>, <name><surname>Peters</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Objective assessment of nonadherence and unknown co-medication in hospitalized patients</article-title>. <source>Eur J Clin Pharmacol</source>
<volume>68</volume>: <fpage>1191</fpage>&#x02013;<lpage>1199</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00228-012-1229-2">http://dx.doi.org/10.1007/s00228-012-1229-2</ext-link>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00228-012-1229-2">10.1007/s00228-012-1229-2</ext-link></comment>
<pub-id pub-id-type="pmid">22354152</pub-id></mixed-citation></ref><ref id="pone.0139302.ref036"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Rivero-Santana</surname><given-names>A</given-names></name>, <name><surname>Perestelo-Perez</surname><given-names>L</given-names></name>, <name><surname>P&#x000e9;rez-Ramos</surname><given-names>J</given-names></name>, <name><surname>Serrano-Aguilar</surname><given-names>P</given-names></name>, <name><surname>De Las Cuevas</surname><given-names>C</given-names></name> (<year>2013</year>) <article-title>Sociodemographic and clinical predictors of compliance with antidepressants for depressive disorders: systematic review of observational studies</article-title>. <source>Patient Prefer Adherence</source>
<volume>7</volume>: <fpage>151</fpage>&#x02013;<lpage>169</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84875046136&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84875046136&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 3 December 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/PPA.S39382">10.2147/PPA.S39382</ext-link></comment>
<pub-id pub-id-type="pmid">23487319</pub-id></mixed-citation></ref><ref id="pone.0139302.ref037"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Cramer</surname><given-names>JA</given-names></name>, <name><surname>Rosenheck</surname><given-names>R</given-names></name> (<year>1998</year>) <article-title>Compliance with medication regimens for mental and physical disorders</article-title>. <source>Psychiatr Serv</source>
<volume>49</volume>: <fpage>196</fpage>&#x02013;<lpage>201</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0031916292&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-0031916292&#x00026;partnerID=tZOtx3y1</ext-link>.
<pub-id pub-id-type="pmid">9575004</pub-id></mixed-citation></ref><ref id="pone.0139302.ref038"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Demoz</surname><given-names>Z</given-names></name>, <name><surname>Legesse</surname><given-names>B</given-names></name>, <name><surname>Teklay</surname><given-names>G</given-names></name>, <name><surname>Demeke</surname><given-names>B</given-names></name>, <name><surname>Eyob</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Medication adherence and its determinants among psychiatric patients in an Ethiopian referral hospital</article-title>. <source>Patient Prefer Adherence</source>
<volume>8</volume>: <fpage>1329</fpage>&#x02013;<lpage>1335</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84908131094&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84908131094&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 27 December 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/PPA.S69702">10.2147/PPA.S69702</ext-link></comment>
<pub-id pub-id-type="pmid">25284991</pub-id></mixed-citation></ref><ref id="pone.0139302.ref039"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Rummel-Kluge</surname><given-names>C</given-names></name>, <name><surname>Schuster</surname><given-names>T</given-names></name>, <name><surname>Peters</surname><given-names>S</given-names></name>, <name><surname>Kissling</surname><given-names>W</given-names></name> (<year>2008</year>) <article-title>Partial compliance with antipsychotic medication is common in patients with schizophrenia</article-title>. <source>Aust N Z J Psychiatry</source>
<volume>42</volume>: <fpage>382</fpage>&#x02013;<lpage>388</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-45849120992&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-45849120992&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 5 August 2015. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/00048670801961107">10.1080/00048670801961107</ext-link></comment>
<pub-id pub-id-type="pmid">18473256</pub-id></mixed-citation></ref><ref id="pone.0139302.ref040"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Horne</surname><given-names>R</given-names></name> (<year>1993</year>) <article-title>One to be taken as directed: Reflections on non-adherence (non-compliance)</article-title>. <source>J Soc Adm Pharm</source>
<volume>10</volume>: <fpage>150</fpage>&#x02013;<lpage>156</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0027860353&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-0027860353&#x00026;partnerID=tZOtx3y1</ext-link>.</mixed-citation></ref><ref id="pone.0139302.ref041"><label>41</label><mixed-citation publication-type="journal">
<name><surname>De las Cuevas</surname><given-names>C</given-names></name>, <name><surname>Pe&#x000f1;ate</surname><given-names>W</given-names></name>, <name><surname>Sanz</surname><given-names>EJ</given-names></name> (<year>2014</year>) <article-title>Risk factors for non-adherence to antidepressant treatment in patients with mood disorders</article-title>. <source>Eur J Clin Pharmacol</source>
<volume>70</volume>: <fpage>89</fpage>&#x02013;<lpage>98</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84891846494&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84891846494&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 7 April 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s00228-013-1582-9">10.1007/s00228-013-1582-9</ext-link></comment>
<pub-id pub-id-type="pmid">24013851</pub-id></mixed-citation></ref><ref id="pone.0139302.ref042"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Medina</surname><given-names>E</given-names></name>, <name><surname>Salv&#x000e0;</surname><given-names>J</given-names></name>, <name><surname>Ampudia</surname><given-names>R</given-names></name>, <name><surname>Maurino</surname><given-names>J</given-names></name>, <name><surname>Larumbe</surname><given-names>J</given-names></name> (<year>2012</year>) <article-title>Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder</article-title>. <source>Patient Prefer Adherence</source>
<volume>6</volume>: <fpage>623</fpage>&#x02013;<lpage>629</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84872827623&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84872827623&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 8 May 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2147/PPA.S34345">10.2147/PPA.S34345</ext-link></comment>
<pub-id pub-id-type="pmid">22969293</pub-id></mixed-citation></ref><ref id="pone.0139302.ref043"><label>43</label><mixed-citation publication-type="journal">
<name><surname>Brain</surname><given-names>C</given-names></name>, <name><surname>Allerby</surname><given-names>K</given-names></name>, <name><surname>Sameby</surname><given-names>B</given-names></name>, <name><surname>Quinlan</surname><given-names>P</given-names></name>, <name><surname>Joas</surname><given-names>E</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS&#x000ae;) in the Swedish COAST-study</article-title>. <source>Eur Neuropsychopharmacol</source>
<volume>23</volume>: <fpage>1754</fpage>&#x02013;<lpage>1762</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-84887608510&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-84887608510&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 7 April 2014. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.euroneuro.2013.09.001">10.1016/j.euroneuro.2013.09.001</ext-link></comment>
<pub-id pub-id-type="pmid">24091164</pub-id></mixed-citation></ref><ref id="pone.0139302.ref044"><label>44</label><mixed-citation publication-type="journal">
<name><surname>Canales</surname><given-names>PL</given-names></name>, <name><surname>Dorson</surname><given-names>PG</given-names></name>, <name><surname>Crismon</surname><given-names>ML</given-names></name> (<year>2001</year>) <article-title>Outcomes assessment of clinical pharmacy services in a psychiatric inpatient setting</article-title>. <source>Am J Heal Pharm</source>
<volume>58</volume>: <fpage>1309</fpage>&#x02013;<lpage>1316</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0035879363&#x00026;partnerID=40&#x00026;md5=8706768c34ffdb37b67a62d144cc516f">http://www.scopus.com/inward/record.url?eid=2-s2.0-0035879363&#x00026;partnerID=40&#x00026;md5=8706768c34ffdb37b67a62d144cc516f</ext-link>.</mixed-citation></ref><ref id="pone.0139302.ref045"><label>45</label><mixed-citation publication-type="journal">
<name><surname>Velligan</surname><given-names>DI</given-names></name>, <name><surname>Wang</surname><given-names>M</given-names></name>, <name><surname>Diamond</surname><given-names>P</given-names></name>, <name><surname>Glahn</surname><given-names>DC</given-names></name>, <name><surname>Castillo</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Relationships among subjective and objective measures of adherence to oral antipsychotic medications</article-title>. <source>Psychiatr Serv</source>
<volume>58</volume>: <fpage>1187</fpage>&#x02013;<lpage>1192</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-34848817407&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-34848817407&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 24 July 2014.
<pub-id pub-id-type="pmid">17766564</pub-id></mixed-citation></ref><ref id="pone.0139302.ref046"><label>46</label><mixed-citation publication-type="journal">
<name><surname>J&#x000f3;nsd&#x000f3;ttir</surname><given-names>H</given-names></name>, <name><surname>Opjordsmoen</surname><given-names>S</given-names></name>, <name><surname>Birkenaes</surname><given-names>AB</given-names></name>, <name><surname>Engh</surname><given-names>JA</given-names></name>, <name><surname>Ringen</surname><given-names>PA</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Medication adherence in outpatients with severe mental disorders: relation between self-reports and serum level</article-title>. <source>J Clin Psychopharmacol</source>
<volume>30</volume>: <fpage>169</fpage>&#x02013;<lpage>175</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-77952142466&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-77952142466&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 30 December 2014.
<pub-id pub-id-type="pmid">20520290</pub-id></mixed-citation></ref><ref id="pone.0139302.ref047"><label>47</label><mixed-citation publication-type="journal">
<name><surname>Viswanathan</surname><given-names>M</given-names></name>, <name><surname>Golin</surname><given-names>CE</given-names></name>, <name><surname>Jones</surname><given-names>CD</given-names></name>, <name><surname>Ashok</surname><given-names>M</given-names></name>, <name><surname>Blalock</surname><given-names>SJ</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Interventions to Improve Adherence to Self-administered Medications for Chronic Diseases in the United States: A Systematic Review</article-title>. <source>Ann Intern Med</source>.</mixed-citation></ref><ref id="pone.0139302.ref048"><label>48</label><mixed-citation publication-type="journal">
<name><surname>Geddes</surname><given-names>JR</given-names></name>, <name><surname>Carney</surname><given-names>SM</given-names></name>, <name><surname>Davies</surname><given-names>C</given-names></name>, <name><surname>Furukawa</surname><given-names>TA</given-names></name>, <name><surname>Kupfer</surname><given-names>DJ</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review</article-title>. <source>Lancet</source>
<volume>361</volume>: <fpage>653</fpage>&#x02013;<lpage>661</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-0037460745&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-0037460745&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 25 July 2014.
<pub-id pub-id-type="pmid">12606176</pub-id></mixed-citation></ref><ref id="pone.0139302.ref049"><label>49</label><mixed-citation publication-type="journal">
<name><surname>Masand</surname><given-names>P</given-names></name>, <name><surname>Narasimhan</surname><given-names>M</given-names></name> (<year>2006</year>) <article-title>Improving Adherence to Antipsychotic Pharmacotherapy</article-title>. <source>Curr Clin Pharmacol</source>
<volume>1</volume>: <fpage>47</fpage>&#x02013;<lpage>56</lpage>. Available: <ext-link ext-link-type="uri" xlink:href="http://www.scopus.com/inward/record.url?eid=2-s2.0-34547551320&#x00026;partnerID=tZOtx3y1">http://www.scopus.com/inward/record.url?eid=2-s2.0-34547551320&#x00026;partnerID=tZOtx3y1</ext-link>. Accessed 28 July 2014.
<pub-id pub-id-type="pmid">18666377</pub-id></mixed-citation></ref></ref-list></back></article>